Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR 79.00
+1.28 (1.65%)
Feb 19, 2026, 5:36 PM CET
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
€624,162
Profits / Employee
€104,388
Market Cap
93.85B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 200,000 |
| emeis Société anonyme | 83,500 |
| Eurofins Scientific SE | 65,000 |
| Clariane SE | 61,798 |
| Ramsay Générale de Santé | 40,494 |
| bioMérieux | 14,754 |
| Sartorius Stedim Biotech | 10,134 |
| Virbac | 6,365 |
Sanofi News
- 1 day ago - Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report - GlobeNewsWire
- 2 days ago - Sanofi, Teva Report Positive Phase 2b Results For Duvakitug - Nasdaq
- 2 days ago - Sanofi announces leadership evolution in Specialty Care Business Unit - PRNewsWire
- 2 days ago - Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's - Nasdaq
- 2 days ago - Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients - Benzinga
- 2 days ago - Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's - GuruFocus
- 2 days ago - Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease - Seeking Alpha
- 2 days ago - Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease - GlobeNewsWire